New collaboration will produce nearly 2 million N95 respirators per year to address the urgent need for affordable access to essential personal protective equipment (PPE) in communities that need them most.
DURHAM, N.C. – Organizations from both the public and private sector have teamed up to launch the Made in NC initiative, a collaboration between Blue Cross and Blue Shield of North Carolina (Blue Cross NC), North Carolina State University’s Nonwovens Institute, Freudenberg Performance Materials, UNC Health, the NC Healthcare Association Strategic Partners and NC Medical Society to manufacture and distribute N95 respirators that will serve the needs of North Carolina health care workers during the coronavirus disease 2019 (COVID-19) pandemic and increase equity in access to personal protective equipment (PPE) in communities that need them most.
Since the onset of the COVID-19 pandemic, demand for N95 respirators and other PPE has outpaced current US manufacturing capabilities, resulting in supply chain challenges in delivering an efficient and reliable source at a reasonable cost. The shortage of critical supplies has left health care providers and essential workers at a higher risk of infection.
The Made in NC collaboration will produce an initial 100,000 to 200,000 N95 respirators per month with plans to quickly ramp up, right here in North Carolina, providing a more consistent and affordable source of PPE for local health care providers. Collaborating organizations include:
The initiative aims to ensure the state’s frontline health care workers receive the critical PPE they need to keep themselves and their communities safe.
Best of Managed Care Cast: Top 5 Episodes From the First Half of 2025
July 18th 2025These interviews are the top episodes, by listens, from among the 21 podcast episodes The American Journal of Managed Care® produced over the first half of 2025. Give them all another listen, and perhaps learn something new.
Read More
From Red Tape to Relief: Rewriting the Rules of Prior Authorization
June 23rd 2025Up to 257 million Americans could benefit from these prior authorization reforms that could have cross-market implications on health care plans administered through commercial insurers, Medicare Advantage, and Medicaid.
Read More
Many Patients Stop GLP-1s Before Reaching Target Dose: Hamlet Gasoyan, PhD
June 19th 2025Discontinuing the weight loss treatment before hitting the recommended maintenance dose contributes to low-value care despite provider follow-up and efforts to manage side effects, says Hamlet Gasoyan, PhD, Cleveland Clinic.
Read More